Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance
- PMID: 12473586
Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance
Abstract
Purpose: Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine derived from T cells and the pituitary gland. However, several types of solid cancers also secrete MIF, and this factor has been suggested to play an important role in carcinogenesis and the progression of malignancy. In this study, we quantified MIF mRNA expression of non-small cell lung cancer tissues and examined its relationship with clinicopathological factors.
Experimental design: MIF mRNAs of both tumor and normal tissues were quantified by a real-time monitoring reverse-transcription PCR in 59 patients with non-small cell lung cancer. The relationship between the grade of MIF expression and clinicopathological factors such as smoking history, cell type, stage, and prognosis was examined to investigate the clinical significance of intratumoral expression of MIF.
Results: The mean copy number of MIF mRNA per 0.08 micro g of total mRNA in tumor tissues was 144,078.00, whereas that of normal lung tissue was 25,438.46 (P < 0.0001). The amounts of MIF proteins revealed by a Western blot analysis correlated well with those of the corresponding mRNAs. Male patients and heavy smokers showed significantly higher expression of MIF. Patients with squamous cell carcinomas showed a higher expression of MIF mRNA than other subjects. In squamous cell carcinoma patients, higher expression of MIF mRNA was significantly associated with unfavorable prognosis (P = 0.0142).
Conclusions: The general intratumoral expression and close relation with smoking suggested that MIF might contribute to tumorigenesis in the lung.
Similar articles
-
Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.Lung Cancer. 2008 Oct;62(1):113-9. doi: 10.1016/j.lungcan.2008.02.014. Epub 2008 Jun 11. Lung Cancer. 2008. PMID: 18550205
-
Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.Cancer. 2000 Jul 15;89(2):334-41. Cancer. 2000. PMID: 10918163
-
Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma.Clin Cancer Res. 2003 Nov 1;9(14):5282-6. Clin Cancer Res. 2003. PMID: 14614010
-
Macrophage migration inhibitory factor (MIF) as a paracrine mediator in the interaction of testicular somatic cells.Andrologia. 2000 Jan;32(1):46-8. Andrologia. 2000. PMID: 10702866 Review.
-
25 Years On: A Retrospective on Migration Inhibitory Factor in Tumor Angiogenesis.Mol Med. 2015 Oct 27;21 Suppl 1(Suppl 1):S19-24. doi: 10.2119/molmed.2015.00055. Mol Med. 2015. PMID: 26605643 Free PMC article. Review.
Cited by
-
Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis.Carcinogenesis. 2013 Dec;34(12):2891-9. doi: 10.1093/carcin/bgt239. Epub 2013 Jul 3. Carcinogenesis. 2013. PMID: 23825153 Free PMC article.
-
Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma.Brain Sci. 2019 Oct 19;9(10):284. doi: 10.3390/brainsci9100284. Brain Sci. 2019. PMID: 31635049 Free PMC article.
-
Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach.Oncotarget. 2018 Apr 3;9(25):17951-17970. doi: 10.18632/oncotarget.24885. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707160 Free PMC article. Review.
-
Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma.Oncol Lett. 2014 Nov;8(5):2267-2275. doi: 10.3892/ol.2014.2513. Epub 2014 Sep 9. Oncol Lett. 2014. PMID: 25289107 Free PMC article.
-
Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.World J Gastroenterol. 2005 Jun 28;11(24):3767-71. doi: 10.3748/wjg.v11.i24.3767. World J Gastroenterol. 2005. PMID: 15968736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous